NICE has published draft guidance recommending interferon beta-1b (Extavia, Novartis), glatiramer acetate (Copaxone, Teva UK Ltd), and interferon beta-1a (Avonex, Biogen Idec Ltd, and Rebif, Merck Serono Ltd) – as treatment options for people with a type of MS called relapsing-remitting MS.